+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adult Growth Hormone Deficiency - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • January 2021
  • Region: Global
  • DelveInsight
  • ID: 5237658
This “Adult Growth Hormone Deficiency - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Adult Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Adult Growth Hormone Deficiency Understanding


Adult Growth Hormone Deficiency: Overview


Adult growth hormone deficiency is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Growth hormone is made by the anterior pituitary gland. It stimulates the release of another hormone called insulin-like growth factor 1 (IGF-1), which is produced mainly by the liver. Together, these hormones stimulate growth in childhood (especially the height) and in adult life psychological well-being and physical performance. GH also has widespread metabolic effects throughout the body.

Symptoms


The symptoms of Adult Growth Hormone Deficiency include:

  • Decrease in the amount of muscle bulk and strength
  • Increase in the amount of fat in the body (especially around the waist)
  • Abnormalities of ‘good' and ‘bad' cholesterol. This can lead to an increase in the risk of heart disease
  • Osteoporosis (brittle bones)
  • Low energy levels and decreased stamina
  • Impaired concentration and memory

Diagnosis


The most common test is the ‘Insulin tolerance test'. This involves giving an injection of insulin to the patient to lower the blood sugar level. During this stress reaction, the body normally releases growth hormone. Failure to produce an adequate amount of growth hormone in response to this insulin induced stress confirms growth hormone deficiency. Alternative tests are also available in which growth hormone-releasing hormone, arginine or glucagon are used to cause growth hormone release. These tests should be carried out in a specialist unit, by experienced staff in performing these tests safely.

Treatment


Adult growth hormone deficiency is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves. This is done using daily injections underneath the skin into the fat tissue around the lower abdomen, with an injection device. The needles are the same as those used by people who inject insulin for diabetes and the injections are virtually painless. Treatment starts as an outpatient clinic with education and support, usually from an endocrine nurse. Once started, individuals are carefully monitored and given regular blood tests. The dosage of the growth hormone is adjusted depending upon the patient's response and results of blood tests.

Adult Growth Hormone Deficiency Emerging Drugs Chapters


This segment of the Adult Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adult Growth Hormone Deficiency Emerging Drugs


Lonapegsomatropin: Ascendis Pharma

Lonapegsomatropin is Somatotropin receptor agonists. It is being developed by Ascendis Pharma and is currently in Phase 3 trial of clinical study.

GX-H9: Genexine

GX-H9 is Somatotropin receptor agonists. GX-H9 (Eftansomatropin) is being developed by Genexine and is currently in Phase 3 trial of clinical study.

Adult Growth Hormone Deficiency: Therapeutic Assessment


This segment of the report provides insights about the different Adult Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Adult Growth Hormone Deficiency


There are approx. 10+ key companies which are developing the therapies for Adult Growth Hormone Deficiency. The companies which have their Adult Growth Hormone Deficiency drug candidates in the most advanced stage, i. e. phase III include, Ascendis Pharma.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Adult Growth Hormone Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adult Growth Hormone Deficiency: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adult Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult Growth Hormone Deficiency drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Adult Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Adult Growth Hormone Deficiency.
  • In January 2018, Strongbridge Pharma announced acquisition of Macrilen (macimorelin) from Aeterna Zentaris.

Adult Growth Hormone Deficiency Report Insights

  • Adult Growth Hormone Deficiency Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Adult Growth Hormone Deficiency Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Adult Growth Hormone Deficiency drugs?
  • How many Adult Growth Hormone Deficiency drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adult Growth Hormone Deficiency?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adult Growth Hormone Deficiency therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Adult Growth Hormone Deficiency and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Ascendis Pharma
  • Genexine
  • Bolder Biotechnology

Key Products

  • Lonapegsomatropin
  • GX-H9
  • BBT-031

Table of Contents

Introduction

Executive Summary

Adult Growth Hormone Deficiency: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Adult Growth Hormone Deficiency - Analytical Perspective

In-depth Commercial Assessment
  • Adult Growth Hormone Deficiency companies’ collaborations, Licensing, Acquisition - Deal Value Trends

Adult Growth Hormone Deficiency Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Lonapegsomatropin: Ascendis Pharma
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

BBT-031: Bolder Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Adult Growth Hormone Deficiency Key Companies

Adult Growth Hormone Deficiency Key Products

Adult Growth Hormone Deficiency- Unmet Needs

Adult Growth Hormone Deficiency- Market Drivers and Barriers

Adult Growth Hormone Deficiency- Future Perspectives and Conclusion

Adult Growth Hormone Deficiency Analyst Views

Adult Growth Hormone Deficiency Key Companies

AppendixList of Tables
Table 1 Total Products for Adult Growth Hormone Deficiency
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Adult Growth Hormone Deficiency
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ascendis Pharma
  • Genexine
  • Bolder Biotechnology